Microbot Medical (NASDAQ: MBOT) outlines 2025 results, 2026 goals

Rhea-AI Filing Summary

Microbot Medical Inc. filed a current report to share that it issued a press release on January 12, 2026. The release reaffirms the company’s achievements in 2025 and announces key anticipated milestones for 2026, highlighting its recent progress and future business, regulatory, or financial targets. The press release is furnished as Exhibit 99.1 and incorporated by reference, and the company includes customary cautionary language that statements about expected future milestones are forward-looking and subject to various risks and uncertainties.

false 0000883975 0000883975 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19871		94-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 12, 2026, Microbot Medical Inc. (the “Company”) issued a press release reaffirming its 2025 achievements and announcing its key 2026 anticipated milestones.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference.

Forward Looking Statements

This Item 8.01 of this Current Report on Form 8-K may contain “forward-looking statements.” Such statements which are not purely historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “intends,” “would,” “could” and “estimates”) are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, business, regulatory and financial milestones.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from time-to-time with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: January 12, 2026

FAQ

What did Microbot Medical (MBOT) disclose in this 8-K filing?

Microbot Medical reported that it issued a press release reaffirming its 2025 achievements and announcing its key anticipated milestones for 2026, furnished as Exhibit 99.1.

What is the main focus of Microbot Medical’s new press release?

The press release focuses on reaffirming the company’s 2025 achievements and outlining key anticipated milestones for 2026, reflecting both past progress and future plans.

How is the Microbot Medical (MBOT) press release made available in the filing?

The press release is furnished as Exhibit 99.1 to the report and is incorporated by reference into the disclosure under Item 8.01.

Does Microbot Medical include forward-looking statement warnings in this disclosure?

Yes. The company notes that statements about future business, regulatory and financial milestones are forward-looking and may differ from actual results due to numerous factors.

Which exchange lists Microbot Medical’s common stock and under what symbol?

Microbot Medical’s common stock is listed on the NASDAQ Capital Market under the trading symbol MBOT.

What items of the 8-K does Microbot Medical use in this report?

The company uses Item 8.01 (Other Events) to describe the press release and Item 9.01 to list the financial statements and exhibits, including Exhibit 99.1.